We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000783:SZSEChangjiang Securities Company Limited Analysis

Data as of 2026-05-24 - not real-time

CN¥8.23

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Changjiang Securities trades at a price‑to‑earnings multiple that is comfortably below the industry average, indicating a valuation discount. Its price‑to‑book ratio hovers around a modest level, supporting the case for relative cheapness. The company delivers robust gross and operating margins, reflecting efficient cost management. Revenue growth remains strong, driven by expanding wealth‑management and brokerage services. Dividend yield is modest but the payout ratio is low, suggesting dividend sustainability. However, the balance sheet shows a high leverage profile, with debt far exceeding equity.
Technically, the stock sits in a neutral trend with the 20‑day moving average above the 50‑day, but the MACD has turned bearish. The relative strength index is near the midpoint, indicating no extreme momentum bias. Volatility over the past month is elevated, while beta is low, pointing to high price swings but limited market‑wide risk. Trading volume is on the rise, adding confidence to price movements. Current price hovers near a key support level, with upside limited by a nearby resistance ceiling. Market sentiment is at an extreme greed phase, which could fuel short‑term buying pressure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • bearish MACD signal
  • elevated short‑term volatility
  • price near key support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • valuation discount relative to peers
  • strong earnings margins
  • sustainable dividend payout

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • robust profitability
  • high leverage and regulatory exposure
  • moderate growth outlook

Key Metrics & Analysis

Financial Health

Revenue Growth34.60%
Profit Margin36.99%
P/E Ratio11.4
ROE10.11%
ROA2.33%
Debt/Equity160.13
P/B Ratio1.2
Op. Cash FlowCN¥12.2B
Industry P/E16.8

Technical Analysis

TrendNeutral
RSI54.9
SupportCN¥7.09
ResistanceCN¥9.24
MA 20CN¥8.10
MA 50CN¥7.55
MA 200CN¥8.03
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Fair ValueCN¥62.62
Target PriceCN¥8.58
Upside/Downside4.25%
GradeUndervalued
TypeBlend
Dividend Yield1.82%

Risk Assessment

Beta0.45
Volatility52.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.